WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201475
Description: AEG40826 (HGS1029) is the hydrochloride salt of a small-molecule inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins with potential antineoplastic activity. IAP inhibitor HGS1029 selectively inhibits the biological activity of IAP proteins, which may restore apoptotic signaling pathways; this agent may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.
MedKoo Cat#: 201475
Synonym: HGS1029; HGS-1029; HGS 1029; AEG40826; AEG-40826; AEG 40826; AEG408262 HCl.
IUPAC/Chemical Name: NONE
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Aegera has developed extremely potent small molecule IAP inhibitors by targeting functional domains on the individual IAP proteins; These compounds possess good pharmacokinetic/pharmacodynamic properties and stability and demonstrate potent anticancer activity, alone and in combination with current cancer therapies and death receptor agonists. In December 2007, Aegera and Human Genome Sciences, Inc. (Nasdaq:HGSI) completed a licensing and collaboration agreement providing HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize AEG40826 (HGS1029) and other small-molecule IAP inhibitors in oncology. Aegera has retained global rights for the use of its small molecules IAP inhibitors in all indications outside oncology. AEG40826/HGS1029 is currently progressing in Phase 1 studies. (source: http://www.aegera.com/aeg40826.php).